A semi-secret government contractor that calls itself Project Vigilant surfaced at the Defcon security conference Sunday with a series of revelations: that it monitors the traffic of 12 regional Internet service providers, hands much of that information to federal agencies, and encouraged one of its "volunteers," researcher Adrian Lamo, to inform the federal government about the alleged source of a controversial video of civilian deaths in Iraq leaked to whistle-blower site Wikileaks in April.

He says the 600-person "volunteer" organization functions as a government contractor bridging public and private sector security efforts. Its mission: to use a variety of intelligence-gathering efforts to help the government attribute hacking incidents.

one of Project Vigilant's manifold methods for gathering intelligence includes collecting information from a dozen regional U.S. Internet service providers (ISPs). Uber declined to name those ISPs, but said that because the companies included a provision allowing them to share users' Internet activities with third parties in their end user license agreements (EULAs), Vigilant was able to legally gather data from those Internet carriers and use it to craft reports for federal agencies. A Vigilant press release says that the organization tracks more than 250 million IP addresses a day and can "develop portfolios on any name, screen name or IP address." "We don't do anything illegal," says Uber. "If an ISP has a EULA to let us monitor traffic, we can work with them. If they don't, we can't."

Ginkgo biloba has failed — again — to live up to its reputation for boosting memory and brain function. Just over a year after a study showed that the herb doesn't prevent dementia and Alzheimer's disease, a new study from the same team of researchers has found no evidence that ginkgo reduces the normal cognitive decline that comes with aging.

In the new study, the largest of its kind to date, DeKosky and his colleagues followed more than 3,000 people between the ages of 72 and 96 for an average of six years. Half of the participants took two 120-milligram capsules of ginkgo a day during the study period, and the other half took a placebo. The people who took ginkgo showed no differences in attention, memory, and other cognitive measures compared to those who took the placebo, according to the study, which was published in this week's Journal of the American Medical Association.